Table I.
Association between AR expression and clinicopathological characteristics in 188 patients with TNBC.
| AR | ||||
|---|---|---|---|---|
| Characteristics | Positive (%) | Negative (%) | χ2 | P-value |
| Age (years) | ||||
| ≤50 | 24 (21.6) | 87 (78.4) | 0.006 | 0.941 |
| >50 | 17 (22.1) | 60 (77.9) | ||
| Menstrual status | ||||
| Pre-menopause | 27 (21.8) | 97 (78.2) | <0.001 | 0.987 |
| Post-menopause | 14 (21.9) | 50 (78.1) | ||
| BMI | ||||
| <24 | 28 (23.5) | 91 (76.5) | 0.563 | 0.453 |
| ≥24 | 13 (18.8) | 56 (81.2) | ||
| Family history | ||||
| No | 36 (23.4) | 118 (76.6) | 1.228 | 0.268 |
| Yes | 5 (14.7) | 29 (85.3) | ||
| Tumor grade | ||||
| I–II | 29 (21.5) | 106 (78.5) | 0.030 | 0.862 |
| III | 12 (22.6) | 41 (77.4) | ||
| Tumor size (cm) | ||||
| ≤5 | 37 (25) | 111 (75) | 4.155 | 0.042 |
| >5 | 4 (10) | 36 (90) | ||
| Lymph node metastasis | ||||
| No | 27 (28.1) | 69 (71.9) | 4.590 | 0.032 |
| Yes | 14 (15.2) | 78 (84.8) | ||
| Clinical stage | ||||
| I–II | 31 (24.4) | 96 (75.6) | 1.553 | 0.213 |
| III | 10 (16.4) | 51 (83.6) | ||
| Ki-67 | ||||
| <14 | 10 (23.3) | 33 (76.7) | 0.068 | 0.794 |
| ≥14 | 31 (21.4) | 114 (78.6) | ||
AR, androgen receptor; TNBC, triple negative breast cancer; BMI, body mass index.